Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 18, Issue 12, 2012, Pages 2209-2217

  Steenholdt, Casper ^a   Al Khalaf, Magid ^a   Brynskov, Jørn ^a   Bendtzen, Klaus ^b   Thomsen, Ole O ^a   Ainsworth, Mark A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

anti TNF antibodies; antidrug antibody; Crohn's disease; inflammatory bowel disease; infliximab; pharmacokinetics; TNF; ulcerative colitis

Indexed keywords

INFLIXIMAB;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84864655177     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22910     Document Type: Article

References (41)

1. Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011; 106 (Suppl 1): S2-25.
2. Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007; 133: 312-339.
3. Dignass A, Van AG, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010; 4: 28-62.
4. Travis SP, Stange EF, Lemann M, et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008; 2: 24-62.
5. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010; 4: 355-366.
6. Yanai H, Hanauer SB,. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011; 106: 685-698.
7. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011; 60: 41-48.
8. Cassinotti A, Travis S,. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis. 2009; 15: 1264-1275.
9. Danese S, Fiorino G, Reinisch W,. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther. 2011; 34: 1-10.
10. Gisbert JP, Panes J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104: 760-767.
11. Ainsworth MA, Bendtzen K, Brynskov J,. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008; 103: 944-948.
12. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol. 2011; 46: 310-318.
13. Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 34: 51-58.
14. Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009; 44: 774-781.
15. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010; 105: 1133-1139.
16. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004; 2: 542-553.
17. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008; 30: 523-529.
18. Biomonitor A/S, Copenhagen, Denmark. www.biomonitor.dk. 2010.
19. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006; 54: 3782-3789.
20. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology. 2007; 46: 1828-1834.
21. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009; 68: 1739-1745.
22. Steenholdt C, Svenson M, Bendtzen K, et al. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. J Crohns Colitis. 2012; 6: 108-111.
23. Steenholdt C, Al-Khalaf M, Ainsworth MA, et al. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohns Colitis. 2012 [Epub ahead of print].
24. Munkholm P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol. 1992; 27: 609-614.
25. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994; 107: 3-11.
26. Bendtzen K,. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheum. 2011; 63: 867-870.
27. Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011; 50: 1445-1452.
28. Steenholdt C, Svenson M, Bendtzen K, et al. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors' reply. Aliment Pharmacol Ther. 2011; 34: 404-405.
29. Xu Z, Seitz K, Fasanmade A, et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol. 2008; 48: 681-695.
30. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876-885.
31. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348: 601-608.
32. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54: 711-715.
33. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4: 1248-1254.
34. Van AG, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008; 134: 1861-1868.
35. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010; 59: 49-54.
36. Kopylov U, Mantzaris GJ, Katsanos KH, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther. 2011; 33: 349-357.
37. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305: 1460-1468.
38. Bendtzen K,. Immunogenicity of anti-TNF antibodies. In:, van de Weert M, Møller EH, eds. Biotechnology: Pharmaceutical Aspects, Vol. VIII. Immunogenicity of Biopharmaceuticals. New York: Springer; 2008. p 189-203.
39. Morell A, Terry WD, Waldmann TA,. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970; 49: 673-680.
40. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005; 366: 1379-1384.
41. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007; 56: 1226-1231.